WCN26-8079 USING AUTOMATED INSULIN DELIVERY (‘ARTIFICAL PANCREAS’) FOR GLYCAEMIC MANAGEMENT IN PEOPLE WITH TYPE 1 DIABETES AND END STAGE KIDNEY DISEASE ON HAEMODIALYSIS

Read full text Summarise with VIRAT
Authors: Panagiotis Pavlou, Lalantha Leelarathna, Thomas Johnston, Rebecca Hyslop, Monika Reddy, Parizad Avari, Rachael Tan, Sufyan Hussain, Janaka J. Karalliedde
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Managing diabetes in end-stage kidney disease (ESKD) in people with type 1 diabetes on haemodialysis (HD) presents unique challenges. There is an unmet need for adaptable therapies in this high risk group. who are prone to glycaemic variability and hypoglycaemia. Automated insulin delivery (AID) systems ('artificial pancreas') may be effective as they can adjust insulin delivery dynamically in line with continuous glucose monitoring data, however there are no studies in HD. This study aimed to evaluate real-world use of AID in HD

Fields of Study & Subjects

Diabetes Management and Research Dialysis and Renal Disease Management Diabetes Management and Education

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105331–105331
Publication date
25 March 2026
Language
EN